Target
Matrix metalloproteinase 13
Description
Anti-Matrix metalloproteinase 13 Antibody, Non-Fucosylated (BioBet-1233ZP) is a human monoclonal IgG antibody against Matrix metalloproteinase 13. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer; Degenerative Bone Diseases; Cardiovascular Disease
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Matrix metalloproteinase 13 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
matrix metallopeptidase 13 (collagenase 3)
Background
Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. Most MMPs are secreted as inactive proproteins which are activated when cleaved by extracellular proteinases. The protein encoded by this gene cleaves type II collagen more efficiently than types I and III. It may be involved in articular cartilage turnover and cartilage pathophysiology associated with osteoarthritis. The gene is part of a cluster of MMP genes which localize to chromosome 11q22.3.
Alternative Names
MMP13; matrix metallopeptidase 13 (collagenase 3); CLG3; MANDP1; MMP-13; collagenase 3; matrix metalloproteinase 13 (collagenase 3)
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with MMP13 include Spondyloepimetaphyseal Dysplasia, Missouri Type and Metaphyseal Dysplasia, Spahr Type.
Related Pathways
Its related pathways are G-protein signaling Ras family GTPases in kinase cascades (scheme) and Cell adhesion_Plasmin signaling.
Function
Participate in the degradation of extracellular matrix proteins, including fibronectin, fibronectin, TNC and ACAN. Three types of helical collagen can be lysed, including type collagen, type collagen and type collagen, but have the highest activity with soluble collagen. It can also degrade type IV, type XIV and type x collagen. It can also activate or degrade key regulatory proteins, such as TGFB1 and CCN2. It plays a role in wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification. Required for normal embryonic bone development and ossification. Play a role in fracture healing through endochondral osteogenesis. Play a role in wound healing, and its mechanisms may include proteolytic activation of TGFB1 and degradation of CCN2. It plays a role in the migration of keratinocytes during wound healing. May play a role in cell migration and tumor cell invasion.
Field of research
Cancer antibody; Cell Biology and Cellular Response antibody; Signaling Transduction antibody
Post-translational modifications
The proenzyme is activated by removal of the propeptide; this cleavage can be effected by other matrix metalloproteinases, such as MMP2, MMP3 and MMP14 and may involve several cleavage steps. Cleavage can also be autocatalytic, after partial maturation by another protease or after treatment with 4-aminophenylmercuric acetate (APMA) (in vitro). N-glycosylated. Tyrosine phosphorylated by PKDCC/VLK.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-1233ZP
Description
The antibody directed to the antigen MMP-13 are used for the treatment of diseases associated with the activity and/or overproduction of MMP-13. MMP-13 is expressed at elevated levels in cancers, degenerative bone diseases, and cardiovascular diseases. Inhibition of the biological activity of MMP-13 can delay the progression of symptoms caused by such diseases or conditions and other desired effects.
Antibody Indication
Cancer; Degenerative Bone Diseases; Cardiovascular Disease
